| December 2016 |
| 27 Dec |
Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data |
 |
| 20 Dec |
Intimation regarding Analyst / Institutional Investor Meet |
|
| 17 Dec |
Transfer of shares to Investor Education and Protection Fund |
|
| 16 Dec |
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Change in Key Managerial Personnel |
|
| 13 Dec |
Intimation regarding Analyst / Institutional Investor Meet |
|
| 13 Dec |
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 |
|
| 06 Dec |
Intimation regarding Analyst / Institutional Investor Meet |
|
| November 2016 |
| 29 Nov |
Biocon's Novel Diabetes Education Initiative for Medical Practitioners 'ABIDE' Awarded by RSSDI |
|
| 22 Nov |
Intimation regarding Analysts / Institutional Investors Meet |
|
| 17 Nov |
Intimation regarding Analysts / Institutional Investors Meet |
|
| 15 Nov |
Intimation regarding Analysts / Institutional Investors Meet |
|
| 11 Nov |
Intimation regarding Analysts / Institutional Investors Meet |
|
| 09 Nov |
Intimation regarding Analysts / Institutional Investors Meet |
|
| 08 Nov |
Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab |
|
| 03 Nov |
Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency |
|
| October 2016 |
| 24 Oct |
Intimation regarding Analyst / Institutional Investor Meet |
|
| 20 Oct |
Unaudited Financial Results for the quarter and period ended Sep. 30, 2016
|
|
| September 2016 |
| 29 Sep |
Intimation regarding Analyst / Institutional Investor Meet |
|
| 23 Sep |
Intimation regarding Analyst / Institutional Investor Meet |
|
| 19 Sep |
Biocon Appoints Suresh Subramanian as Head of Branded Formulations (India) Business |
|
| 14 Sep |
Intimation regarding Analyst / Institutional Investor Meet |
|
| 07 Sep |
Intimation regarding Analyst / Institutional Investor Meet |
|
| 01 Sep |
Intimation regarding Analyst / Institutional Investor Meet |
|
| August 2016 |
| 26 Aug |
Intimation regarding Analyst / Institutional Investor Meet |
|
| 25 Aug |
Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency |
|
| 24 Aug |
Intimation regarding Analyst / Institutional Investor Meet |
|
| 17 Aug |
Intimation regarding Analyst / Institutional Investor meet |
|
| 9 Aug |
Intimation regarding Analyst / Institutional Investor meet |
|
| 2 Aug |
Intimation regarding Analyst / Institutional Investor meet |
|
| July 2016 |
| 28 July |
Biocon Initiates "Ek Prayaas" Nationwide Awareness Program on Hepatitis C |
|
| 21 July |
Biocon Reports a Strong Q1FY17
Revenues at Rs 952 Crore, up by 11 %; EBITDA Up 15% to Rs 271 Crore
Net Profit Up 17% at Rs 147 Crore |
|
| 21 July |
Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency |
|
| 15 July |
Biocon's Insulin Glargine Launched in Japan |
|
| June 2016 |
| 27 Jun |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 24 Jun |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 23 Jun |
Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India |
|
| 22 Jun |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 16 Jun |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 10 Jun |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 04 Jun |
Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting |
|
| 03 Jun |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 01 Jun |
Intimation regarding
Analyst/Institutional Investor meet |
|
| May 2016 |
| 30 May |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 26 May |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 26 May |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 18 May |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 12 May |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 5 May |
Intimation regarding
Analyst/Institutional Investor meet |
|
| 3 May |
Intimation regarding
Analyst/Institutional Investor meet |
|
| April 2016 |
| 26 Apr |
Biocon Q4FY16 Net Profit at Rs 361 Cr Revenue Crosses Rs 1,000 Cr; Up 17% FY 16 Revenues up 14% at Rs 3,570 Cr Net Profit at Rs 896 Cr | |
| 26 Apr |
Intimation Regarding Appointment of Director |
|
| March 2016 |
| 29 Mar |
Intimation regarding Analysts/Institutional
Investors Meet |
|
| 28 Mar |
Biocon's Insulin Glargine Receives
Regulatory Approval in Japan |
|
| 23 Mar |
Intimation regarding Analysts/Institutional
Investors Meet |
|
| 17 Mar |
Biocon Inks Co-Development &
Commercialization Agreement with
Lab PiSA for rh-Insulin in USA |
|
| 17 Mar |
Agreement for development and
commercialisation of rh-Insulin for US
market |
|
| 15 Mar |
Intimation regarding Analysts/Institutional
Investors Meet |
|
| 11 Mar |
Declaration of Interim Dividend |
|
| 08 Mar |
Intimation regarding Analysts/Institutional
Investors Meet |
|
| 04 Mar |
Intimation regarding Analysts/Institutional
Investors Meet |
|
| February 2016 |
| 24 Feb |
Intimation regarding Analysts/Institutional
Investors Meet |
|
| 15 Feb |
Press Release:
Biocon Gets its First Generic Formulation
Approval in EU; On Track to Launch
Rosuvastatin Tablets in FY 17 |
|
| 03 Feb |
Press Release:
Biocon Academy Introduces First Of Its
Kind Career Advancement Program In
'Quality Control Microbiology' in
Collaboration with BITS Pilani |
|
| January 2016 |
| 21 Jan |
Press Release:
Biocon Q3FY16 Net Profit Up 13% at
Rs 103 Crore |
|
| 21 Jan |
Press Release:
Biocon Announces Data from Key Studies
for Insulin Tregopil |
|
